- Home
- MNPR vs MYND Comparison
MNPR vs MYND Comparison
Compare MNPR & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- MYND
- Stock Information
- Founded
- MNPR 2014
- MYND 1998
- Country
- MNPR United States
- MYND Cayman Islands
- Employees
- MNPR N/A
- MYND N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- MYND Other Consumer Services
- Sector
- MNPR Health Care
- MYND Real Estate
- Exchange
- MNPR Nasdaq
- MYND Nasdaq
- Market Cap
- MNPR 113.5M
- MYND 121.0M
- IPO Year
- MNPR 2019
- MYND 2017
- Fundamental
- Price
- MNPR $30.68
- MYND $1.87
- Analyst Decision
- MNPR Strong Buy
- MYND
- Analyst Count
- MNPR 3
- MYND 0
- Target Price
- MNPR $27.33
- MYND N/A
- AVG Volume (30 Days)
- MNPR 93.6K
- MYND 109.3K
- Earning Date
- MNPR 11-08-2024
- MYND 02-05-2025
- Dividend Yield
- MNPR N/A
- MYND N/A
- EPS Growth
- MNPR N/A
- MYND N/A
- EPS
- MNPR N/A
- MYND N/A
- Revenue
- MNPR N/A
- MYND $357,050,000.00
- Revenue This Year
- MNPR N/A
- MYND N/A
- Revenue Next Year
- MNPR N/A
- MYND N/A
- P/E Ratio
- MNPR N/A
- MYND N/A
- Revenue Growth
- MNPR N/A
- MYND N/A
- 52 Week Low
- MNPR $1.55
- MYND $0.61
- 52 Week High
- MNPR $38.50
- MYND $6.95
- Technical
- Relative Strength Index (RSI)
- MNPR 76.63
- MYND 46.89
- Support Level
- MNPR $20.16
- MYND $2.06
- Resistance Level
- MNPR $25.97
- MYND $2.60
- Average True Range (ATR)
- MNPR 2.75
- MYND 0.49
- MACD
- MNPR 0.41
- MYND -0.06
- Stochastic Oscillator
- MNPR 90.25
- MYND 3.40
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About MYND Mynd.ai Inc.
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more.